Administration
Administer orally or by IM, direct IV, or sub-Q injection; also may administer percutaneously by topical application of a transdermal system (Transderm Scop).
When administered orally or IM for the prevention of motion sickness, generally administer 1 hour (range: 0.5–1.5 hours) before anticipated exposure to motion.
When used preoperatively, administer 30–60 minutes prior to the anticipated time of induction of anesthesia or at the same time other preanesthetic medications (e.g., opiates, sedatives) are administered, since scopolamine may cause behavioral changes in patients with pain or anxiety. (See CNS Effects under Cautions.)
Transdermal Administration
To prevent motion sickness, apply at least 4 hours (e.g., 4–24 hours) before anticipated exposure to motion.
To prevent postoperative nausea and vomiting, apply the evening before scheduled surgery. 
For use in cesarean section, apply 1 hour prior to surgery to minimize exposure of the fetus to the drug. 
Transdermal system should not be cut; only one transdermal system should be worn at any time.
Prior to administration, wipe area behind the ear with a clean, dry tissue to ensure it is dry.
To expose adhesive surface, peel and discard the clear plastic protective strip prior to administration; avoid finger contact with exposed adhesive layer to prevent contamination of the fingers with scopolamine.
Apply to dry, hairless area of skin behind the ear (postauricular) by firmly pressing the system with the adhesive side touching the skin.
If the system becomes dislodged during the intended period of use (up to 72 hours), remove it and replace with another system at a different postauricular site.
Generally not affected by limited exposure to water (e.g., during bathing or swimming).
Dosage
Tablets and injection: Available as scopolamine hydrobromide; dosage expressed in terms of the salt.
Pediatric Patients
Usual Dosage
IM, IV, Sub-Q
Children 6 month to 3 years of age: 0.1–0.15 mg
Children 3–6 years of age: 0.2–0.3 mg
Motion Sickness
Sub-Q
Usually 0.006 mg/kg (6 mcg/kg).
Postoperative Nausea and Vomiting
Sub-Q
Usually 0.006 mg/kg (6 mcg/kg).
Adults
Usual Dosage
Oral
0.4–0.8 mg.
IM, IV, Sub-Q
0.32–0.65 mg; may be repeated 3 or 4 times daily if necessary.
Motion Sickness
Oral
Initially, 0.25–0.8 mg 1 hour before exposure to motion; subsequently, 0.25–0.8 mg 3 times daily as needed and tolerated.
IM, IV, Sub-Q
Usually 0.32–0.65 mg; may be repeated 3 or 4 times daily if necessary.
Alternatively, 0.2–1 mg.
Transdermal
Usually, one scopolamine system applied ≥4 hours prior to anticipated exposure to motion.
May use for up to 72 hours if necessary or may remove during the 72-hour period when an antiemetic effect is no longer required.
When necessary to continue beyond 72 hours, remove the initially applied system and place another system behind the ear at a different site.
Postoperative Nausea and Vomiting
Transdermal
Apply one transdermal system the evening before scheduled surgery. 
For cesarean section, apply 1 hour prior to surgery to minimize exposure of the infant to the drug. 
Allow patch to remain in place for 24 hours following surgery, then remove and discard. 
Surgery
Obstetric Anmesia or Preoperative Sedation
Usually 0.32–0.65 mg.
Inhibition of Salivation
Usually 0.32–0.65 mg. Alternatively, 0.2–0.6 mg has been suggested.
Amnestic Effect
Usually 0.32–0.65 mg.
Sedative or Tranquilizing Effect
Usually 0.6 mg.
 Detailed Scopolamine dosage information
